The invention provides a compound of formula (I):
The invention provides a compound of formula (I):
The invention provides a compound of formula (I):
or a pharmaceutically acceptable salt thereof; wherein, A, B, ring C, R3, R4, R5, R6, and R7 have the meaning as described herein, and compositions containing such compounds and methods for using such compounds and compositions.
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/5365 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and at least one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 25/00 - Drugs for disorders of the nervous system
Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.
A61K 31/185 - AcidsAnhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
A61K 31/405 - Indole-alkanecarboxylic acidsDerivatives thereof, e.g. tryptophan, indomethacin
A61K 31/4418 - Non-condensed pyridinesHydrogenated derivatives thereof having a carbocyclic ring directly attached to the heterocyclic ring, e.g. cyproheptadine
A61K 31/455 - Nicotinic acid, i.e. niacinDerivatives thereof, e.g. esters, amides
A61K 31/4745 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenanthrolines
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
3.
CELLULAR ASSAYS AND METHODS TO ASSESS MHC-PEPTIDE-TCR INTERACTIONS AND KINETICS
Compositions, systems and methods for quantifying binding rate kinetics for receptor molecules and MHC molecules are provided. The quantitative data produced can be of an accuracy and quantity suitable for generating predictive models. More specifically, assays described herein can accommodate analysis of large varieties of MHC associated peptides.
G01N 33/557 - ImmunoassayBiospecific binding assayMaterials therefor using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
G01N 33/58 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving labelled substances
C07D 498/22 - Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
150mg/mL omalizumab formulation for use in a method of treatment of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, wherein the omalizumab is administered subcutaneously by a syringe.
Techniques described herein include, for example, generating a feature map for an input image, generating a plurality of concentric crops of the feature map, and generating an output vector that represents a characteristic of a structure depicted in a center region of the input image using the plurality of concentric crops. Generating the output vector may include, for example, aggregating sets of output features generated from the plurality of concentric crops, and several methods of aggregating are described. Applications to classification of a structure depicted in the center region of the input image are also described.
G06V 10/77 - Processing image or video features in feature spacesArrangements for image or video recognition or understanding using pattern recognition or machine learning using data integration or data reduction, e.g. principal component analysis [PCA] or independent component analysis [ICA] or self-organising maps [SOM]Blind source separation
G06V 10/80 - Fusion, i.e. combining data from various sources at the sensor level, preprocessing level, feature extraction level or classification level
G06V 10/82 - Arrangements for image or video recognition or understanding using pattern recognition or machine learning using neural networks
G06V 20/69 - Microscopic objects, e.g. biological cells or cellular parts
7.
LUBRICATED FLUID EXCHANGE NEEDLE FOR ENHANCED PERFORMANCE OF REFILLABLE IMPLANTABLE OCULAR DRUG DELIVERY SYSTEM
An exchange needle device having an elongate needle structure having an elongate tube extending distally from a proximal hub and an outer cannula extending distally from the proximal hub. The outer cannula surrounds at least a proximal end region of the elongate tube forming an annular space between the outer surface of the elongate tube and the inner surface of the outer cannula. The distal end of the outer cannula is located a distance proximal to the distal opening of the elongate tube. A lubricious coating is on the outer surface of the outer cannula and the outer surface of the elongate tube extending distal to the distal end of the outer cannula, the lubricious coating covering at least a portion of the working length of the elongate needle structure. Related devices, systems, and methods of use are provided.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
8.
ENHANCED SEPTUM RETENTION FOR IMPLANTED OCULAR DELIVERY SYSTEMS
An ophthalmic drug delivery device including a body defining a refillable reservoir; an extrascleral flange projecting from a proximal end of the body and defining a bore extending from an upper surface of the flange into the reservoir; a septum including an upper surface connected to a lower surface by a curved outer surface. The curved outer surface of the septum forms a first bond with the bore. A perimeter region of the upper surface of the septum lies flush with a plane of the upper surface of the flange and a central region of the upper surface lies below the perimeter region. An elastomeric encasement extends over at least the upper surface of the flange and the upper surface of the septum and prevents displacement of the septum relative to the bore upon penetration by a needle. Related devices, systems, and methods are provided.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
The present invention provides methods for purifying a polypeptide from a composition comprising the polypeptide and at least one contaminant and formulations comprising the polypeptide purified by the methods. The methods for purifying include cation exchange material and/or mixed mode material.
B01D 15/36 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
B01D 15/38 - Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups , e.g. affinity, ligand exchange or chiral chromatography
C07K 1/16 - ExtractionSeparationPurification by chromatography
G01N 30/88 - Integrated analysis systems specially adapted therefor, not covered by a single one of groups
Provided are, inter alia, multispecific antigen binding proteins, or antigen-binding fragments thereof, comprising one or more mutations in the VH/VL domains and/or CH1/CL domains, pharmaceutical compositions comprising same, isolated nucleic acids, vectors, and host cells encoding/expressing same, method of making the multispecific antigen binding proteins, computer readable media for evaluating multispecific antigen binding proteins, and libraries.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
G16B 5/00 - ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
G16B 20/00 - ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
Particular embodiments provide a method for anomaly detection in images of tissue. An image processing system may receive an image of a tissue sample. A set of tiles may be generated from the image of the tissue sample. The set of tiles may be input into an anomaly detection model comprising a generator model comprising functional skip-connections and a Markovian discriminator model. The anomaly detection model may be trained to isolate a feature space of normal tissue samples. Anomaly scores may be computed for the set of tiles, and an assessment may be generated for the image of the tissue sample based on the anomaly scores for the set of tiles. The assessment may include a reconstructed heatmap of the image of the tissue sample, wherein colors of the heatmap are selected based on the anomaly scores.
A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg/mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.
A method of treating a patient with of one or more of: allergic asthma; chronic rhinosinusitis with nasal polyps; chronic spontaneous urticaria; nasal polyps; food allergy; moderate to severe persistent asthma in patients with a positive skin test or in vitro reactivity to a perennial aeroallergen and symptoms inadequately controlled with inhaled corticosteroids, the method comprising administering 150 mg/mL omalizumab formulation, wherein the omalizumab is administered subcutaneously by a syringe.
C07K 16/42 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against immunoglobulins (anti-idiotypic antibodies)
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
A61M 5/32 - NeedlesDetails of needles pertaining to their connection with syringe or hubAccessories for bringing the needle into, or holding the needle on, the bodyDevices for protection of needles
Provided herein are diagnostic and therapeutic methods for the treatment of cancer using polygenic risk scores (PRSs) for liver damage. In particular, the invention provides methods for patient selection and methods of treatment.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
15.
PRODUCTION OF HETEROMULTIMERIC PROTEINS USING MAMMALIAN CELLS
Described herein are methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins) capable of specifically binding to more than one target. The targets may be, for example, different epitopes located on a single molecule or located on different molecules.
A device configured to guide creation of an incision in a sclera of an eye including an elongate handle and a footplate having a plurality of struts defining a central opening extending between an upper surface and a lower surface of the footplate. A first strut of the plurality of struts has a proximal-facing blade guide surface that is straight and extends between two lateral struts of the plurality of struts. A second strut of the plurality of struts has a proximal-facing limbal guide surface that is curved. The blade guide surface is separated a distance from the limbal guide surface to identify a target location for creating an incision relative to a limbus of the eye. The blade guide surface has a length between the two lateral struts that limits a length of the incision that can be created using a cutting blade inserted through the central opening.
In one embodiment, a method includes, for each of a set of samples, receiving data input that includes dimensions of a sample area, a percentage of the sample area being viable cells, and a percentage of the sample area exhibiting necrosis. The method includes, for each of the set of samples, computing a percentage of the sample area being stroma. The method includes, for each of the set of samples, computing weighting factors. The method includes computing a weighted percentage of the set of samples being viable cells based on the computed weighting factor and percentage of the sample area being viable cells for each of the set of samples. The method includes determining that a specified condition is detected in the set of samples based on the computed weighted percentage of the set of samples being viable cells satisfying a threshold correlating with an indication of the specified condition.
G16B 15/00 - ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
Methods are provided for the adjuvant treatment of operable HER2-positive primary breast cancer in human patients by administration of pertuzumab in addition to chemotherapy and trastuzumab. The methods reduce the risk of recurrence of invasive breast cancer or death for a patient diagnosed with HER2-positive early breast cancer (eBC) compared to administration of trastuzumab and chemotherapy, without pertuzumab.
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
19.
APOPTOSIS INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE AND AUTOIMMUNE DISEASES
The Walter and Eliza Hall Institute of Medical Research (Australia)
Inventor
Bruncko, Milan
Ding, Hong
Doherty, George A.
Elmore, Steven W.
Hasvold, Lisa A.
Hexamer, Laura
Kunzer, Aaron R.
Song, Xiaohong
Souers, Andrew J.
Sullivan, Gerard M.
Tao, Zhi-Fu
Wang, Gary T.
Wang, Le
Wang, Xilu
Wendt, Michael D.
Mantei, Robert
Hansen, Todd M.
Abstract
Disclosed are compounds which inhibit the activity of anti-apoptotic Bcl-2 proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic Bcl-2 protein.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
20.
COMPOSITIONS AND METHODS FOR TREATING MULTIPLE SCLEROSIS
The present invention relates to methods for treating multiple sclerosis (MS) in a patient which in some cases involves subcutaneously administering an anti-CD20 antibody into the patient at a dose of about 920 mg. Compositions, formulations and articles of manufacture with instructions for such use are also included.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61P 25/00 - Drugs for disorders of the nervous system
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
21.
ANTI-IgE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES
The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.
The present invention relates to pharmaceutical compositions comprising Akt protein kinase inhibitors with therapeutic activity against diseases such as cancer as well as processes for their preparation and their use as medicament.
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
The presently disclosed subject matter provides antibodies that bind KLB and FGFR1, and methods of using the same. In certain embodiments, an antibody of the present disclosure includes a bispecific antibody that binds to an epitope present on FGFR1 and binds to an epitope present on KLB.
C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/71 - ReceptorsCell surface antigensCell surface determinants for growth factorsReceptorsCell surface antigensCell surface determinants for growth regulators
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein are antibodies such as human or humanized antibodies with a modified heavy chain variable (VH) domain such that the antibodies adopt a constrained conformation (e.g., an i-shaped format) upon engaging the antigen(s) the antibodies bind to, thereby confer agonistic activities. In some cases, the antibodies are full-length antibodies (e.g., IgG antibodies). In some cases, the antibodies are monovalent antibodies (e.g., Fabs). In some cases, the antibodies target receptors which require clustering for activation (e.g., TNFR superfamily receptors). In some cases, the antibodies target two antigens on a molecule that have two or more subunits (e.g., an IL-2 receptor). Also provided herein are methods of making and using such antibodies and libraries for discovering or screening such antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
25.
ANTI-IGE ANTIBODY THERAPY FOR MULTIPLE FOOD ALLERGIES
The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.
The present disclosure provides methods and kits for treating or preventing an allergic reaction to a food allergen consumed by a human subject with one or more food allergies. In particular, the present disclosure provides prophylactic therapies comprising administration of an anti-IgE antibody at a specific dose to a human subject who is allergic to one or more food allergens.
A method of classifying a tissue sample by a classification system includes identifying, by the classification system, a plurality of tiles corresponding to whole-slide image data of the tissue sample; generating, by the classification system, a plurality of semantic masks corresponding to the plurality of tiles, each one of the plurality of semantic masks identifying a cell boundary and a cell type of each cell within a corresponding tile of the plurality of tiles; generating, by the classification system, a plurality of cellular features for each tile of the plurality of tiles based on a corresponding one of the plurality of semantic masks; and classifying, by the classification system, the tissue sample based on the plurality of cellular features for each one of the plurality of tiles.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
The present invention features RNA polynucleotide constructs comprising sequences targeting Huntingtin mRNA, polynucleotide constructs comprising a sequence encoding for such RNA constructs, and primary microRNA scaffolds. Constructs comprising sequences targeting Huntingtin mRNA and/or encoding for sequences targeting Huntingtin mRNA can be used, for example, for inhibiting mutant HTT expression and/or treating Huntington disease.
Described here are compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and their use and preparation.
Described here are compounds of Formula (I) and pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising same, and their use and preparation.
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/497 - Non-condensed pyrazines containing further heterocyclic rings
A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Pharmaceutical asset tracking systems and methods for pharmaceutical asset tracking are disclosed. The system comprises a pharmaceutical asset tracker to transmit pharmaceutical asset information to a communications device. The pharmaceutical asset information comprises an identifier for a pharmaceutical asset associated with the pharmaceutical asset tracker in a defined area. The communications device is responsive to communications via a crowdsourcing protocol, and the pharmaceutical asset tracker transmits the pharmaceutical asset information to the communications device via the responsive crowdsourcing protocol. The system comprises a server configured to receive the pharmaceutical asset information and location information from the communications device. The server may determine, based on the location information, a location of the asset, and provide for display information regarding a group of pharmaceutical assets determined to be at a specified location. The group is identified based on pharmaceutical asset information for each of the assets in the group.
A method may include determining, within a first positron emission tomography and computed tomography (PET-CT) scan depicting a plurality of regions of a body, a first region including a lesion. A first portion of the first PET-CT scan depicting the first region but not a second region of the plurality of regions may be extracted to generate a second PET-CT scan having one or more initial dimensions. The one or more initial dimensions of the second PET-CT scan may be adjusted to one or more target dimensions by at least adding, to the second PET-CT scan, one or more voxels, and determining a value of each of the one or more voxels added to the second PET-CT scan. A segmentation model may be trained based on a training dataset that includes the second PET-CT scan adjusted to the one or more target dimensions.
The present invention relates to methods, uses, and compositions for the treatment of cancer (e.g., a lung cancer; a cervical cancer; a breast cancer; a head and neck cancer; a liver cancer; a bladder cancer; a gastric cancer; an esophageal cancer; a pancreatic cancer; a kidney or renal cancer; a melanoma; an ovarian cancer; or a colorectal cancer). More specifically, the invention concerns the treatment of patients having cancer with an anti-TIGIT antagonist antibody, including treatment with an anti-TIGIT antagonist antibody in a combination therapy.
A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
A61K 31/675 - Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
A61K 31/7068 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61P 35/04 - Antineoplastic agents specific for metastasis
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present application discloses high-concentration monoclonal antibody formulations suitable for subcutaneous administration, e.g. via a pre-filled syringe. In particular, it discloses a formulation comprising a spray dried monoclonal antibody at a concentration of about 200 mg/mL or more suspended in a non-aqueous suspension vehicle where the viscocity of the suspension vehicle is less than about 20 centipoise. Also disclosed are: a subcutaneous administration device with the formulation therein, a method of making the formulation, a method of making an article of manufacture comprising the suspension formulation, use of the formulation in the preparation of a medicament, and a method of treating a patient with the formulation.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
34.
Random Heteropolymer Excipients For High Protein Concentration Formulations
This application relates to random polymer libraries and specific polymers that can be used, for example, in stabilizing high concentration protein compositions, such as high concentration antibody compositions.
in situin situ. Advantageously, the method can be effectively used to detect barcode sequences in formalin-fixed paraffin-embedded (FFPE) tissue samples.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
Provided herein are antibodies such as human or humanized antibodies with a modified heavy chain variable (VH) domain such that the antibodies adopt a constrained conformation (e.g., an i-shaped format) upon engaging the antigen(s) the antibodies bind to, thereby confer agonistic activities. In some cases, the antibodies are full-length antibodies (e.g., IgG antibodies). In some cases, the antibodies are monovalent antibodies (e.g., Fabs). In some cases, the antibodies target receptors which require clustering for activation (e.g., TNFR superfamily receptors). In some cases, the antibodies target two antigens on a molecule that have two or more subunits (e.g., an IL-2 receptor). Also provided herein are methods of making and using such antibodies and libraries for discovering or screening such antibodies.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The present invention relates to the treatment of liver cancer, e.g., hepatocellular carcinoma (HCC), e.g., resectable HCC. More specifically, the invention pertains to the treatment of patients having an HCC by administering (i) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab); (ii) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab), a VEGF antagonist (e.g., bevacizumab), and an anti-TIGIT antagonist antibody (e.g., tiragolumab); or (iii) a combination of a bispecific antibody that binds to PD-1 and LAG3 (e.g., tobemstomig) and a VEGF antagonist (e.g., bevacizumab).
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/32 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products from oncogenes
The present invention relates to the treatment of liver cancer, e.g., hepatocellular carcinoma (HCC), e.g., resectable HCC. More specifically, the invention pertains to the treatment of patients having an HCC by administering (i) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab); (ii) a combination of a PD-1 axis binding antagonist (e.g., atezolizumab), a VEGF antagonist (e.g., bevacizumab), and an anti-TIGIT antagonist antibody (e.g., tiragolumab); or (iii) a combination of a bispecific antibody that binds to PD-1 and LAG3 (e.g., tobemstomig) and a VEGF antagonist (e.g., bevacizumab).
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
Provided herein are methods of treatment of cancers, specifically multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies in combination with anti-B cell maturation factor (BCMA)/anti-CD3 bispecific antibodies.
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
40.
Prevention of disulfide bond reduction during recombinant production of polypeptides
The invention concerns methods for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Provided herein are methods for assessing splice-switching ASOs using a reporter to detect splicing of a cryptic sequence located in the reporter pre-mRNA.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
Provided herein are methods for generating a solid antigen/carrier protein gel for immunohistochemistry (IHC), as well as gels, kits and methods of use thereto. In particular, the methods, gels and kits provided herein include a purified antigen such as a polypeptide antigen, and a carrier protein such as an albumin protein, an egg white protein or mixture of egg white proteins, gelatin, or poly-lysine. Examples are provided in which the purified antigen is cross-linked to the carrier protein in the solid antigen/carrier protein gel.
The present disclosure provides methods of identifying a disease-specific immunogenic peptide through a series of selection steps. Immunogenic epitopes identified by methods of the present disclosure are applicable for use in peptide-based immunotherapy, preferably cancer therapy. Furthermore, the methods of the present disclosure may be performed in a high-throughput manner and serve as a means of personalized vaccine development and therapy. Also provided are compositions of immunogenic peptides as well as methods of treatment comprising said compositions.
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
45.
METHODS OF PRODUCING TISSUE-DERIVED EPITHELIAL ORGANOIDS AND USES THEREOF
The present disclosure provides methods of preparing tissue-derived epithelial organoids. In particular, the present disclosure provides tissue-derived epithelial organoids embedded in hydrogel suspended in a medium. The present disclosure further provides methods of using such organoids.
The invention provides methods and compositions for classifying kidney cancer (e.g., RCC, e.g., an inoperable, locally advanced, or metastatic RCC); methods and compositions for treating kidney cancer in a patient, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) and a VEGF antagonist (e.g., bevacizumab) to the patient. Also provided are compositions, pharmaceutical compositions, kits, and articles of manufacture for use in classifying and treating kidney cancer in a patient.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
54.
PHARMACEUTICAL COMPOUND, SALTS THEREOF, FORMULATION THEREOF, AND METHODS OF MAKING AND USING SAME
A61J 3/10 - Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
A61K 9/00 - Medicinal preparations characterised by special physical form
The present disclosure relates to pharmaceutical formulations of anti-TIGIT monoclonal antibodies that are suitable for co administration or co-formulation with anti-PD-L1 monoclonal antibodies. The present disclosure also relates to articles of manufacture comprising such pharmaceutical formulations and methods of treating cancer using the pharmaceutical formulations and to use of the pharmaceutical formulations for the treatment of cancer or the manufacture of a medicament for treating cancer. The present disclosure also relates to articles of manufacture comprising single doses of anti-TIGIT monoclonal antibodies or both anti-TIGIT and anti-PD-L1 monoclonal antibodies and methods of treating cancer using such articles of manufacture and the formulations contained therein.
A61K 38/47 - Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
A61K 47/18 - AminesAmidesUreasQuaternary ammonium compoundsAmino acidsOligopeptides having up to five amino acids
A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
The presently disclosed subject matter relates to multi-vector recombinase mediated cassette exchange approaches to achieve targeted integration of sequences of interest for the generation host cells expressing recombinant proteins, e.g., monoclonal antibodies, as well as compositions derived from the same, e.g., bispecific antibodies, and other complex format proteins, e.g., membrane protein complexes, and other difficult to express molecules.
The present disclosure provides methods for treating lupus nephritis in an individual that has lupus. In some embodiments, the methods comprise administering to the individual an effective amount of a type II anti-CD20 antibody. In other aspects, the present disclosure provides methods for treating membranous nephropathy.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/34 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 31/573 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 37/06 - Immunosuppressants, e.g. drugs for graft rejection
58.
GENE EXPRESSION MARKERS AND TREATMENT OF MULTIPLE SCLEROSIS
The present invention concerns markers of multiple sclerosis, their use, and treatment with IL-17 antagonists, including IL-17 antibodies, of subjects with increased levels of such markers.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/564 - ImmunoassayBiospecific binding assayMaterials therefor for pre-existing immune complex or autoimmune disease
59.
MACROPHAGE SIGNATURES FOR DIAGNOSTIC AND THERAPEUTIC METHODS FOR LYMPHOMA
The present invention provides diagnostic methods, therapeutic methods, and compositions for the treatment of lymphoma (e.g., a diffuse large B-cell lymphoma (e.g., a germinal-center B-cell- like or activated B-cell-like diffuse large B-cell lymphoma). The invention is based, at least in part, on the discovery that macrophage biomarkers are useful in methods of identifying, diagnosing, or predicting the therapeutic efficacy of treatment with an anti-CD79b immunoconjugate (e.g., polatuzumab vedotin) and an anti-CD20 antibody (e.g., obinutuzumab or rituximab).
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
60.
SOLID FORMS OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3-FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9-TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL AND PROCESSES FOR PREPARING FUSED TRICYCLIC COMPOUNDS COMPRISING A SUBSTITUTED PHENYL OR PYRIDINYL MOIETY, INCLUDING METHODS OF THEIR USE
Provided herein are solid forms, salts, and formulations of 3-((1R,3R)-1-(2,6-difluoro-4-((1-(3-fluoropropyl)azetidin-3-yl)amino)phenyl)-3-methyl-1,3,4,9-tetrahydro-2H-pyrido[3,4-b]indol-2-yl)-2,2-difluoropropan-1-ol, processes and synthesis thereof, and methods of their use in the treatment of cancer.
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The present disclosure relates generally to rapid-release pharmaceutical dosage unit tablets containing small molecule API medicines. In some instances the API is an inhibitor of Ras proteins, such as K-Ras, H-Ras, and N-Ras, that have a G12C mutation. Such tablets also contain a disintegrant and an excipient. More specifically, the present disclosure relates to pharmaceutical dosage unit tablets containing divarasib, or a pharmaceutically acceptable salt thereof, an extragranular disintegrant, and an extragranular excipient, and to processes for preparing the tablets from granules formed by dry granulation.
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in immunology; Pharmaceutical preparations for the treatment of renal disorders; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, Pharmaceutical preparations for the treatment of cardio-vascular diseases and disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of metabolic diseases and disorders, Pharmaceutical preparations for the treatment of cardio-vascular diseases and disorders; Pharmaceutical preparations for the treatment of renal disorders; Pharmaceutical preparations for use in immunology
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for use in immunology; Pharmaceutical preparations for the treatment of metabolic diseases and disorders, Pharmaceutical preparations for the treatment of cardio-vascular diseases and disorders; Pharmaceutical preparations for the treatment of renal disorders
05 - Pharmaceutical, veterinary and sanitary products
Goods & Services
Pharmaceutical preparations for the treatment of metabolic diseases and disorders, Pharmaceutical preparations for the treatment of cardio-vascular diseases and disorders; Pharmaceutical preparations for use in immunology; Pharmaceutical preparations for the treatment of renal disorders
67.
COUNTERFACTUAL GENERATION OF MOLECULAR CONFORMATIONS
A method may include determining a first conformer of a molecule. A first uncertainty metric of the first conformer of the molecule may be determined. A counterfactual generative model may be applied to generate a second conformer of the molecule associated with a second uncertainty metric. The counterfactual generative model may generate the second conformer by sampling from a latent space populated by a plurality of embeddings of molecular conformers. The molecular analysis model may be applied to determine, based on a structure of the second conformer, the molecular property of the molecule. Related systems and computer program products are also provided.
Cell culture media comprising antioxidants are provided herein as are methods of using the media for cell culturing and polypeptide production from cells. Compositions comprising polypeptides, such as therapeutic polypeptides. produced by the methods herein are also provided.
The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.
The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.
A61K 31/4545 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/4178 - 1,3-Diazoles not condensed and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of myelin-related disorders.
The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of myelin-related disorders.
A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
71.
METHODS OF TREATING TGF BETA-RELATED DISORDERS WITH ANTI-TRANSFORMING GROWTH FACTOR BETA 3 ANTIBODIES
C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
A61P 9/00 - Drugs for disorders of the cardiovascular system
A61P 11/00 - Drugs for disorders of the respiratory system
A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
Provided herein are high throughput methods for optimizing and manufacturing various lipid nanoparticle (LNP) compositions and uses thereof. In some embodiments, the present disclosure provides a high-throughput screening method for manufacturing a LNP composition comprising, obtaining at least two intermixable solutions comprising a payload and a plurality of molecules capable of self-assembly, and mixing said at least two solutions under a set of controlled conditions, by which injection sequence, speed, volume, phase ratio and mixing duration are varied. In various embodiments, the present disclosure enables optimal encapsulation efficiency, particle size distribution, purification and particle recovery rate, and formulation stability to be determined. The methods disclosed herein enable efficient optimization of manufacturing conditions for preparation of LNP-based therapeutics.
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
An app for guided self-capture of images may display a graphical user interface (GUI) on a screen of a mobile computing device with a camera. The GUI may present instructions to capture images of a specific area of concern on a patient's body, including a graphical representation of the specific area of the user's body posed in a predefined position. The GUI may display the graphical representation in conjunction with a view appearing in a lens of the camera. The app may then store one or more images captured by the camera and display, in the GUI, the one or more stored images together with instructions to review the stored images. In response to receiving user input approving one or more of the stored images, the app may then transmit the approved images to a system associated with a physician or clinician.
The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 31/4523 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
79.
SPIROCYCLIC BICYCLIC MODULATORS OF CHOLESTEROL BIOSYNTHESIS AND THEIR USE FOR PROMOTING REMYELINATION
The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.
The subject matter described herein is directed to myelin-promoting compounds of Formula I and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the treatment of disorders, such as myelin-related disorders.
A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
80.
HUMANIZED AND AFFINITY MATURED ANTIBODIES TO FcRH5 AND METHODS OF USE
The present invention relates to anti-FcRH5 antibodies, including anti-FcRH5 antibodies comprising an FcRH5 binding domain and a CD3 binding domain (e.g., FcRH5 T cell-dependent bispecific (TDB) antibodies), and methods of using the same.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
The present disclosure relates to compounds and salts thereof that are useful for modulating target polypeptides and proteins, in particular BRM. Also disclosed are pharmaceutical compositions comprising the compounds, or a salt (e.g., a pharmaceutically acceptable salt) thereof, and methods of using such compounds and salts in the treatment of various BRM-mediated and/or BRG1-mediated diseases or disorders.
The present disclosure provides methods and compositions for determining the risk of a patient being non-responsive to a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody and methods and compositions for treating inflammatory bowel disease (IBD) with a therapeutic dose of an anti-TNF-like ligand 1A (TL1A) antibody.
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
83.
CLEARANCE PREDICTION ACCORDING TO ANTIBODY PROPERTY ANALYSIS
e.g., etc., etc.) derived from biophysical molecular models and protein language model (pLM) embeddings derived from trained deep-learning protein language models (pLMs). A trained clearance prediction model predicts nonspecific clearance of a given antibody sequence according to the physicochemical features and the embeddings.
G16C 20/00 - Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
84.
METHODS AND COMPOSITIONS FOR REDUCING ANTIBODY VISCOSITY
e.g.e.g.e.g., an antibody, an antigen-binding fragment thereof, or an antibody construct). Also provided are antigen binding polypeptide variants produced by the methods. Further provided are related libraries and methods of screening such libraries. Also provided are methods of identifying one or more amino acids in an antibody, an antigen binding fragment of an antibody, or an antibody construct that affect the viscosity of the antibody, the antigen binding fragment, or the antibody construct. Also provided are exemplary antibody variable domains with reduced viscosity.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
85.
THREE-DIMENSIONAL MOLECULE GENERATION BY DENOISING VOXEL GRIDS
A voxelized representation of an input molecule may be updated by applying a molecule design computation model that has been trained to approximate a data distribution of molecules exhibiting one or more desired properties. The molecule design computation model may update the voxelized representation of the input molecule to increase a likelihood of a resultant updated voxelized representation being in the data distribution. A voxelized representation of an output molecule may be generated based on the updated voxelized representation. For example, where the molecule design computation model has been trained to approximate a noisy data distribution populated by noisy voxelized representations of the molecules exhibiting the one or more desired properties, the voxelized representation of the output molecule may be generated by denoising the updated voxelized representation in order to map the updated voxelized representation from the noisy data distribution to the true data distribution.
A voxelized representation of an input molecule may be encoded to generate an embedding of the input molecule having a fewer quantity of features than the voxelized representation of the input molecule. A molecule design computation model may be applied to update the embedding of the input molecule. The molecule design computation model may be trained to approximate a data distribution of molecules exhibiting one or more desired properties by ingesting as input a corrupted embedding of a voxelized representation of a sample molecule exhibiting the one or more desired properties and recovering an embedding of the voxelized representation of the sample molecule. The molecule design computation model may update the embedding of the input molecule to increase a likelihood of a resultant updated embedding within the data distribution. A voxelized representation of an output molecule may be generated by at least decoding the resultant updated embedding.
Described herein are methods, systems, and programming for determining a tumor immunophenotype of an image of a tumor. Some embodiments include dividing an image into tiles depicting tumor epithelium and/or tumor stroma. For each tile, an epithelium-immune cell density and a stroma-immune cell density may be calculated based on a number of immune cells identified in the tumor epithelium and the tumor stroma, respectively. Based on the epithelium-immune cell density and the stroma-immune cell density, an inflammation type of the type may be determined, and a tumor immunophenotype may be determined based on each tile's inflammation type.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
89.
OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER
Provided herein are acyclic oxazepinyl compounds useful in the treatment on cancers.
Provided herein are acyclic oxazepinyl compounds useful in the treatment on cancers.
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
The present disclosure relates to methods of slowing cognitive decline in mild-to-moderate and moderate Alzheimer's disease, and other Tau pathologies, using anti-Tau antibodies. The disclosure provides first-in-class immunotherapy for use in reducing clinical decline in mild-to-moderate AD and moderate AD, in particular, significantly reducing rate of decline in cognitive capacity to a clinically meaningful extent, and significantly retaining memory. The disclosure also relates to use of anti-Tau antibodies to intercept cell-to-cell spread of pathological Tau in the brains of patients with AD or related Tauopathies.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A plurality of molecule designs may be generated computationally. One or more property computation models may be applied to determine multiple properties of each molecule design. Each property computation model may be trained to approximate a probability distribution of the possible values of a corresponding property. A cumulative distribution function indicator corresponding to an expected multivariate rank may be determined for each molecule design based on the output of the property computation models. The multivariate rank of a molecule design may quantify the probability that none of its properties can be improved without degrading at least one other property. One or more molecule designs may be selected as candidates for wet lab assessment based on the cumulative distribution function indicator of each molecule design. The molecule designs that are selected for wet lab assessment may exhibit incrementally better properties than those from previous design iterations.
Systems and methods for managing progression of a clinical trial. Input data for a machine learning model is formed, based on longitudinal data for clinical trial cohort. The input data corresponds to input features and the cohort includes a plurality of subjects. A clinical outcome output is generated for each subject, using the machine learning model and a portion of the input data corresponding to each subject. Feature importance values are generated, based on the machine learning model generating the clinical outcome output for each subject. The feature importance values include, for each subject, a set of feature importance values for a set of input features. A ratio of interest is computed using the plurality of feature importance values. An output is generated using the ratio of interest in which the output indicates whether the cohort should proceed to a next phase of the clinical trial.
G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
93.
METHODS OF TREATING RELAPSING MULTIPLE SCLEROSIS USING AN INHIBITOR OF BRUTON'S TYROSINE KINASE
This application relates generally to analyzing mutations in tumors, and more particularly, to systems and methods for phasing mutations in tumors of subjects (e.g., cancer patients). An exemplary method for phasing mutations in a tumor of a subject comprises enumerating, based on tumor DNA and/or RNA sequence reads, a set of unique mutation patterns observed in the plurality of sequence reads; counting the set of unique patterns observed in the sequence reads to calculate a quantity of each of the unique mutation patterns and/or a quantity of each combination of unique mutation pattern and a transcript group; determining mutation pattern probabilities; and inputting the mutation pattern quantities and the mutation pattern probabilities into a statistical model to estimate at least one of a set of haplotype-existence probabilities that each of the haplotypes exists, a set of haplotype prevalences, and a set of haplotype-transcript prevalences.
An apparatus includes a body and a pair of rigid legs extending from the body. The body includes an engagement feature configured to engage a deployment instrument. The legs are parallel with each other. Each leg has a sharp tip. The legs both extend along a plane. The body defines a guide opening. The guide opening is oriented transversely relative to the plane associated with the legs. The guide opening is sized to receive a cannula having a generally flat profile. The guide opening is configured to guide the cannula through a sclerotomy at a substantially tangential orientation.
A61F 9/00 - Methods or devices for treatment of the eyesDevices for putting in contact-lensesDevices to correct squintingApparatus to guide the blindProtective devices for the eyes, carried on the body or in the hand
A61F 9/013 - Methods or devices for eye surgery for compensation of ocular refraction
100.
6-SUBSTITUTED-3-PHENYL-ISOINDOLIN-1-ONES AS CBL-B INHIBITORS SELECTIVE OVER C-CBL
C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
C07D 405/14 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
